Rilertinib Mesylate

甲磺酸瑞厄替尼

Report date: 2026/03/06 20:02:51
NME

Base Information

Drug NameRilertinib Mesylate
Drug Alias Name奥瑞替尼Rilertinib甲磺酸瑞厄替尼Rilertinib mesylate甲磺酸奥瑞替尼 +[10] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionEGFR T790M inhibitorsEGFR L858R inhibitorsEGFR d746–750 inhibitors +[4] 
TargetsEGFR T790MEGFR L858REGFR d746–750 +[4] 
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell Lung
Global Approved IndicationsCarcinoma, Non-Small-Cell Lung
Approved Indications in ChinaCarcinoma, Non-Small-Cell Lung
Original Approved Country/TerritoryMainland China
Original Approved Date2024/06/11
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesNanjing Sanhome Pharmaceutical Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesNanjing Sanhome Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursCarcinoma, Non-Small-Cell Lung
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A